Pancreatic ductal adenocarcinoma (PDAC) is caused by genetic mutations in four genes: KRAS proto-oncogene and GTPase (), tumor protein P53 (), cyclin-dependent kinase inhibitor 2A (), and mothers against decapentaplegic homolog 4 (), also called the big 4. The changes in tumors are very complex, making their characterization in the early stages challenging. Therefore, the development of innovative therapeutic approaches is desirable. The key to overcoming PDAC is diagnosing it in the early stages. Therefore, recent studies have investigated the multifaced characteristics of PDAC, which includes cancer cell metabolism, mesenchymal cells including cancer-associated fibroblasts and immune cells, and metagenomics, which extend to characterize various biomolecules including RNAs and volatile organic compounds. Various alterations in the -dependent as well as -independent pathways are involved in the refractoriness of PDAC. The optimal combination of these new technologies is expected to help treat intractable pancreatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599774 | PMC |
| http://dx.doi.org/10.3390/biom12101503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Palliative Care Following Aborted Cancer Surgery: Results of a Prospective Feasibility Trial.
Ann Surg Open
December 2024
Division of Palliative Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: Although resection is generally necessary for curative-intent treatment of most solid organ cancers, surgery is occasionally aborted due to intraoperative findings. Following aborted cancer surgery, patients have unique care needs that specialized palliative care (PC) providers may be best equipped to manage. We hypothesized that early ambulatory PC referral following aborted cancer surgery would be feasible and acceptable.
View Article and Find Full Text PDFEnhancing Perioperative Outcomes of Pancreatic Surgery with Wearable Augmented Reality Assistance System: A Matched-Pair Analysis.
Ann Surg Open
December 2024
Department of General, Visceral, and Oncological Surgery, Klinikum Saarbrücken, Saarbrücken, Germany.
Objective: The present study aimed to evaluate the safety of the first wearable augmented reality assistance system (ARAS) specifically designed for pancreatic surgery and its impact on perioperative outcomes.
Background: Pancreatic surgery remains highly complex and is associated with a high rate of perioperative complications. ARAS, as an intraoperative assistance system, has the potential to reduce these complications.
ITGB4/BNIP3 Activates Autophagy and Reduces MHC-I Expression to Mediate Tumour Immune Escape in Pancreatic Cancer Cell Lines.
Immunology
December 2024
Department of Hepatobiliary Surgery, Municipal Hospital Affiliated to Taizhou University, Taizhou, Zhejiang, China.
This study attempted to identify the relevant pathways involved in autophagy activation of pancreatic cancer and explore the mechanisms underlying immune evasion. Western blot (WB) was used to detect the expression of ITGB4, BNIP3, autophagy-related proteins and MHC-I. Co-immunoprecipitation (Co-IP) was used to verify the binding mode of ITGB4 and BNIP3.
View Article and Find Full Text PDFThe Discovery of a Novel AXL/Triple Angiokinase Inhibitor Based on 6-Chloro-Substituted Indolinone and Side Chain Methyl Substitution Inhibiting Pancreatic Cancer Growth and Metastasis.
J Med Chem
December 2024
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
In this study, we discovered and identified a novel AXL/triple angiokinase inhibitor by rational structural modification based on the structure of triple angiokinase inhibitor Nintedanib. We found that potently inhibited AXL expression with the IC value of 3.75 nM and possessed similar inhibitory activity on KDR as Nintedanib.
View Article and Find Full Text PDFThe safety and feasibility of robotic pancreaticoduodenectomy: A multicenter retrospective assessment of 425 patients in Japan.
J Hepatobiliary Pancreat Sci
December 2024
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background/purpose: The Japanese public health insurance system has recently covered robotic pancreaticoduodenectomy (RPD). This study aimed to review the results of RPD during the introductory period and elucidate its safety and feasibility in Japan.
Methods: Consecutive data of 425 patients who underwent RPD were retrospectively collected from 10 high-volume centers in Japan between April 2020 and September 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!